Deutsche Bank AG Lowers Holdings in Recursion Pharmaceuticals, Inc. $RXRX

Deutsche Bank AG reduced its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 5.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 206,370 shares of the company’s stock after selling 11,353 shares during the quarter. Deutsche Bank AG owned about 0.05% of Recursion Pharmaceuticals worth $1,092,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Headlands Technologies LLC lifted its holdings in shares of Recursion Pharmaceuticals by 85.7% in the 1st quarter. Headlands Technologies LLC now owns 165,850 shares of the company’s stock worth $877,000 after buying an additional 76,536 shares during the period. LCM Capital Management Inc bought a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at about $63,000. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Recursion Pharmaceuticals by 93.2% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 387,237 shares of the company’s stock worth $2,048,000 after acquiring an additional 186,767 shares during the period. Blair William & Co. IL lifted its stake in Recursion Pharmaceuticals by 854.2% in the first quarter. Blair William & Co. IL now owns 114,500 shares of the company’s stock worth $606,000 after acquiring an additional 102,500 shares during the period. Finally, R Squared Ltd bought a new position in Recursion Pharmaceuticals during the 1st quarter worth about $72,000. 89.06% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Najat Khan sold 36,599 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the sale, the insider owned 668,197 shares in the company, valued at approximately $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Stock Up 3.3%

NASDAQ:RXRX opened at $4.94 on Monday. The company’s 50-day simple moving average is $5.46 and its 200-day simple moving average is $5.74. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The stock has a market capitalization of $2.14 billion, a P/E ratio of -2.78 and a beta of 0.93.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The firm had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company’s revenue was up 33.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) EPS. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RXRX shares. Needham & Company LLC restated a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an “equal weight” rating and a $5.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.00.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.